Comparison of pre-treatment and in-vivo dosimetry for advanced radiotherapy of prostate cancer
Comparison of pre-treatment and in-vivo dosimetry for advanced radiotherapy of prostate cancer
Background: the usage of advanced radiotherapy techniques requires validation of a previously calculated dose with the precise delivery with a linear accelerator. This study aimed to review and evaluate new verification methods of dose distribution. Moreover, our purpose was to define an internal protocol of acceptance for in-vivo measurements of dose distribution.
Materials and methods: this study included 43 treatment plans of prostate cancer calculated using the Monte Carlo algorithm. All plans were delivered using the Volumetric Modulated Arc Therapy (VMAT) technique of advanced radiotherapy by the linear accelerator Elekta VersaHD. The dose distribution was verified using: MatriXX, iViewDose, and in-vivo measurements. The verification also included recalculation of fluence maps of quality assurance plans in another independent algorithm.
Results: the acceptance criterion of 95% points of dose in agreement was found for pre-treatment verification using MatriXX; the average γ value was 99.09 ± 0.93 (SD) and 99.64 ± 0.35 (SD) for recalculation in the Collapse Cone algorithm. Moreover, using the second algorithm in the verification process showed a positive correlation ρ = 0.58, p < 0.001. However, verification using iViewDose in a phantom and in-vivo did not meet this γ-pass rate.
Conclusions: evaluation of gamma values for in-vivo measurements utilizing iViewDose software was helpful to establish an internal dosimetry protocol for prostate cancer treatments. We assumed value at a minimum of 50% points of the dose in agreement with the 3%/3 mm criterion as an acceptable compliance level. The recalculated dose distribution of QA plans in regard to the Collapse Cone algorithm in the other treatment planning system can be used as a pre-treatment verification method used by a medical physicist in their daily work. The effectiveness of use in iViewDose software, as a pre-treatment tool, is still debatable, unlike the MatriXX device.
189-197
Bartnikowska, Agnieszka
eb6b1201-126e-4262-a4f6-0f8694c7eb52
Cieslik, Grzegorz
0c9a8b9e-a9dd-49ce-a314-f2a6a361f54e
Mlodzik, Mateusz
53f27b4c-e17d-4f09-a47f-59fdf4845ef9
Garcia-Argibay, Miguel
e5a6941e-4dcc-401a-9de4-09557c8856ef
2022
Bartnikowska, Agnieszka
eb6b1201-126e-4262-a4f6-0f8694c7eb52
Cieslik, Grzegorz
0c9a8b9e-a9dd-49ce-a314-f2a6a361f54e
Mlodzik, Mateusz
53f27b4c-e17d-4f09-a47f-59fdf4845ef9
Garcia-Argibay, Miguel
e5a6941e-4dcc-401a-9de4-09557c8856ef
Bartnikowska, Agnieszka, Cieslik, Grzegorz, Mlodzik, Mateusz and Garcia-Argibay, Miguel
(2022)
Comparison of pre-treatment and in-vivo dosimetry for advanced radiotherapy of prostate cancer.
Reports of Practical Oncology & Radiotherapy, 27 (2), .
(doi:10.5603/RPOR.A2022.0027).
Abstract
Background: the usage of advanced radiotherapy techniques requires validation of a previously calculated dose with the precise delivery with a linear accelerator. This study aimed to review and evaluate new verification methods of dose distribution. Moreover, our purpose was to define an internal protocol of acceptance for in-vivo measurements of dose distribution.
Materials and methods: this study included 43 treatment plans of prostate cancer calculated using the Monte Carlo algorithm. All plans were delivered using the Volumetric Modulated Arc Therapy (VMAT) technique of advanced radiotherapy by the linear accelerator Elekta VersaHD. The dose distribution was verified using: MatriXX, iViewDose, and in-vivo measurements. The verification also included recalculation of fluence maps of quality assurance plans in another independent algorithm.
Results: the acceptance criterion of 95% points of dose in agreement was found for pre-treatment verification using MatriXX; the average γ value was 99.09 ± 0.93 (SD) and 99.64 ± 0.35 (SD) for recalculation in the Collapse Cone algorithm. Moreover, using the second algorithm in the verification process showed a positive correlation ρ = 0.58, p < 0.001. However, verification using iViewDose in a phantom and in-vivo did not meet this γ-pass rate.
Conclusions: evaluation of gamma values for in-vivo measurements utilizing iViewDose software was helpful to establish an internal dosimetry protocol for prostate cancer treatments. We assumed value at a minimum of 50% points of the dose in agreement with the 3%/3 mm criterion as an acceptable compliance level. The recalculated dose distribution of QA plans in regard to the Collapse Cone algorithm in the other treatment planning system can be used as a pre-treatment verification method used by a medical physicist in their daily work. The effectiveness of use in iViewDose software, as a pre-treatment tool, is still debatable, unlike the MatriXX device.
Text
88875-341086-1-PB
- Version of Record
More information
Submitted date: 9 January 2022
Accepted/In Press date: 27 January 2022
e-pub ahead of print date: 9 March 2022
Published date: 2022
Identifiers
Local EPrints ID: 489001
URI: http://eprints.soton.ac.uk/id/eprint/489001
PURE UUID: 9f0a6026-b9ed-49f1-96bb-cb683ad866a7
Catalogue record
Date deposited: 10 Apr 2024 16:59
Last modified: 11 Apr 2024 02:09
Export record
Altmetrics
Contributors
Author:
Agnieszka Bartnikowska
Author:
Grzegorz Cieslik
Author:
Mateusz Mlodzik
Author:
Miguel Garcia-Argibay
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics